

**Submission**  
Home > Submission

You can use the options below to view your submission. Where appropriate you can also add to and update your submission and send the details for approval.

Submission Details	
Status	Accepted
Open Date	01/10/2018
Deadline Date	30/10/2018
Date Submitted	26/10/2018
Type	Performance In Delivering
NHS provider	Maldstone and Tunbridge Wells NHS Trust

Showing records 1 to 10 of 10.  
Pages: 1

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
32534	16/LO/1717	212505	ACE-QL-309 A randomised, multicentre, open-label, phase 3 study of Acalabrutinib (ACP-196) versus Investigator's choice of either Idelalisib plus Rituximab or Bendamustine plus Rituximab in subjects with relapsed or refractory chronic lymphocytic leukaemia	Number Agreed	3	3	Date Agreed	28/02/2018	0	15/12/2017	0	Withdrawn By Sponsor	Site closed by sponsor due to lack of recruitment
32535	16/EE/0463	214371	Completion-1 An open-label multicentre phase IIIb study to assess the safety and efficacy of rhotectinib (LEE011) in combination with letrozole for the treatment of men and postmenopausal women with hormone receptor positive (HR+) HER2-negative (HER2-) ad	Number Agreed	6	6	Date Agreed	01/12/2019	5	31/10/2017	5	Recruitment Finished	
32536	14/YH/1056	147421	AB10004 Study - A Multicenter, Randomised, Open-Label, three-parallel groups, phase 2-3 study to evaluate the efficacy and safety of masitinib with dexamethasone, gemtacinib with dexamethasone and the combination of masitinib, gemtacinib and dexamethasone	Number Agreed	4	4	Date Agreed	06/06/2017	1	28/02/2018	1	Withdrawn By Sponsor	Sponsor closed as study futile
32537	16/EM/0332	205699	MAXIMISE: Managing axial manifestations in psoriatic arthritis with secukinumab, a randomised, double-blind, placebo-controlled, multicentre, 52 week study to assess the efficacy and safety of Secukinumab 150mg or 300mg s.c. in patients with active p	Number Agreed	4	4	Not Available / Not Agreed			28/03/2018	4	Recruitment Finished	
32543	13/LO/1557	135995	CALM-NET: A Phase 4, Multicentre, Open Label, Single Group Exploratory Study to Assess the Clinical Value of Enumeration of Circulating Tumour Cells (CTCs) to Predict Clinical Symptomatic Response and Progression Free Survival in Patients receiving D	Number Agreed	2	2	Not Available / Not Agreed			07/07/2018	0	Recruitment Finished	Rare pt population, difficult to screen/recruit eligible pts
32544	17/LO/0441	222471	KEYNOTE-604 MK-3475: A phase III randomised double-blind placebo-controlled trial of pembrolizumab (MK-3475) in combination with etoposide/platinum (Cisplatin or Carboplatin) for the first-line treatment of subjects with extensive stage small cell lu	Number Agreed	4	4	Date Agreed	05/03/2018	1	10/07/2018	3	Recruitment Finished	Recruitment study reached overall recruitment target
33216	14/NW/1258	161891	ARAMIS 3104007 ORION - A multicentre, randomised, double-blind, placebo-controlled, phase III efficacy and safety study of ODW-201 in men with high risk non-metastatic castration-resistant prostate cancer.	Number Agreed	4	4	Not Available / Not Agreed			09/03/2018	1	Recruitment Finished	
33217	16/LO/1106	207909	A randomised double blind phase III study of Pembrolizumab ( ) plus Chemotherapy vs Placebo plus Chemotherapy for previously untreated inoperable locally recurrent or metastatic triple negative breast cancer (keynote 355)	Number Agreed	4	4	Not Available / Not Agreed			03/07/2018	0	Recruitment Finished	Although C&C issued not activated for recruitment due to capacity issues with delivery team - sponsor aware.
			KEYNOTE 522 - A Phase III randomized double blind study to evaluate Pembrolizumab plus Chemotherapy vs Placebo plus	Number Agreed			Not Agreed						Overall study

Submission ID	Submission Number	Submission Title	Number Agreed	Available / Not Agreed	Date Agreed	03/07/2018	05/09/2018	Recruitment Finished	Notes
33218	171/LO/0347	221524 Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)	4	4	01/04/2018	0	0	Recruitment Finished	pts not ill enough to meet incl/exc criteria making it difficult to consent. pts
33219	171/LO/0825	223457 GS-US-445-4189 A randomised phase 2 double-blind placebo-controlled study to assess the safety and efficacy of filgotinib GS-9876 and GS-4059 in adult subjects with active Sjogren's syndrome (SJSST)	2	2	01/04/2018	0	0	Recruitment Finished	pts not ill enough to meet incl/exc criteria making it difficult to consent. pts

Showing records 1 to 10 of 10.  
Pages: 1

< Back

Copyright (c) Exbos Limited 2013. All Rights Reserved. Web site developed in the City of Leeds, England by [Exbos Limited](#) the bespoke software specialists.

